Table 2. Etravirine drug interactions preventing safe co-administration of the indicated agent.
| Co-administered drug | Change in ETR concentration | Change in co-administered drug concentration | Other considerations |
|---|---|---|---|
| NNRTIs | |||
| Efavirenz | Decreases ETR | No clinical benefit to combining NNRTIs | |
| Nevirapine | Decreases ETR | No clinical benefit to combining NNRTIs | |
| Delavirdine | Increases ETR | No clinical benefit to combining NNRTIs | |
| Unboosted PI* | |||
| Atazanavir | Decreases atazanavir | ||
| Fosamprenavir | Increases amprenavir | ||
| Nelfinavir | Increases nelfinavir | ||
| Indinavir | Decreases indinavir | ||
| Boosted PI‡ | |||
| Atazanavir/ritonavir | Increases ETR | Decreases atazanavir | |
| Tipranavir/ritonavir | Decreases ETR | ||
| Fosamprenavir/ritonavir | Increases amprenavir | ||
| High dose ritonavir (600 mg twice daily) | Decreases ETR | ||
| Anticonvulsants | |||
| Carbamazepine | Decreases ETR | Potent CYP450 inducer | |
| Phenobarbitol | Decreases ETR | Potent CYP450 inducer | |
| Phenytoin | Decreases ETR | Potent CYP450 inducer | |
| Antimycobacterials | |||
| Rifampin | Decreases ETR | Potent CYP450 inducer | |
| Rifapentine | Decreases ETR | Potent CYP450 inducer | |
| St. John's Wort | Decreases ETR | ||
*
PI without addition of low dose ritonavir.
‡
PI in combination with low dose ritonavir.
ETR: Etravirine; NNRTI: Non-nucleoside reverse transcriptase inhibitor; PI: Protease inhibitor.
Taken from [17].